DBV Technologies S.A. (NASDAQ:DBVT)‘s stock had its “overweight” rating reiterated by equities researchers at Morgan Stanley in a research report issued to clients and investors on Friday. They presently have a $72.00 price objective on the stock, up from their prior price objective of $70.00. Morgan Stanley’s target price would suggest a potential upside of 50.25% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 target price on the stock in a report on Tuesday, August 29th. Deutsche Bank AG started coverage on shares of DBV Technologies in a report on Friday, June 23rd. They issued a “buy” rating and a $46.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of DBV Technologies in a report on Thursday, July 6th. BidaskClub upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Jefferies Group LLC restated a “buy” rating on shares of DBV Technologies in a report on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $54.86.

DBV Technologies (DBVT) traded up 3.79% during midday trading on Friday, hitting $47.92. 288,699 shares of the company were exchanged. The stock has a 50 day moving average of $43.75 and a 200-day moving average of $38.44. The stock’s market capitalization is $2.20 billion. DBV Technologies has a 1-year low of $31.87 and a 1-year high of $48.11.

TRADEMARK VIOLATION WARNING: “DBV Technologies S.A. (DBVT) Stock Rating Reaffirmed by Morgan Stanley” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/06/dbv-technologies-s-a-dbvt-pt-raised-to-72-00-at-morgan-stanley.html.

Several hedge funds have recently made changes to their positions in DBVT. Dynamic Technology Lab Private Ltd bought a new stake in shares of DBV Technologies during the 2nd quarter valued at $222,000. Victory Capital Management Inc. bought a new stake in shares of DBV Technologies during the 1st quarter valued at $303,000. Airain ltd bought a new stake in shares of DBV Technologies during the 2nd quarter valued at $333,000. Sit Investment Associates Inc. bought a new stake in shares of DBV Technologies during the 2nd quarter valued at $698,000. Finally, Jane Street Group LLC bought a new stake in shares of DBV Technologies during the 1st quarter valued at $853,000. Hedge funds and other institutional investors own 45.52% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.